Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Robert Snidow

Emergency Medicine Princeton, WV Medical Doctor

NPI 1730121898 CMS profile 810883

122 12Th Street Ext, Princeton, WV 24740

Open in the dashboard

General payments

$235

11 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Snidow of Princeton, WV is reported in the CMS Open Payments database as having received $235 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $199 9
2024 General $35 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Snidow
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Robert Snidow were reported at $199. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Robert Snidow Emergency Medicine median Middle half National median
2019 $0 $51 $18–$128 $163
2020 $0 $29 $16–$99 $114
2021 $0 $40 $18–$124 $132
2022 $0 $49 $20–$134 $149
2023 $0 $51 $22–$142 $160
2024 $35 $52 $22–$150 $164
2025 $199 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. AbbVie, Inc. $52 2 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $38 2 payments
  3. ITI, Inc. $37 2 payments
  4. Seqirus USA Inc $34 1 payment
  5. Lilly USA, LLC $19 1 payment
  6. Hologic, LLC $19 1 payment
  7. Pfizer Inc. $19 1 payment
  8. Exact Sciences Corporation $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $235 11 payments
Products named General payments · program years 2024–2025
  1. VRAYLAR $52 2 payments
  2. JARDIANCE $38 2 payments
  3. Fluad $34 1 payment
  4. Flucelvax $34 1 payment
  5. CAPLYTA $20 1 payment
  6. THINPREP 2000 PROCESSOR $19 1 payment
  7. Aptima $19 1 payment
  8. MOUNJARO $19 1 payment
  9. ZEPBOUND $19 1 payment
  10. PREVNAR 20 $19 1 payment
  11. Other $72 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

36

Median for Family Practice: 1,826

Drug cost

$179

Median for Family Practice: $120,094

Branded share of claims

0%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rosuvastatin Calcium Generic 12 $83
Metoprolol Succinate Generic 11 $64
Amlodipine Besylate Generic 13 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$58,427

Of which drugs: $40,741

Medicare patients

337

Average age 76

Services billed

867

191 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 39%
Arthritis 39%
Ischemic heart disease 30%
Depression 23%
Chronic kidney disease 21%
COPD 20%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 128 128 $18,816
Vaccine for influenza for injection into muscle 90662 Office 225 225 $18,410

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record